Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service superficial venous ablation cases in Arkansas: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (235 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 23 | 1,388 | 29% |
| 2020 | 16 | 909 | 32% |
| 2021 | 17 | 977 | 37% |
Radiofrequency, laser, and adhesive ablation of the saphenous veins; office and vein-clinic heavy. Professional codes (what the surgeon bills): CPT 36475, 36478, 36482.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 98% of the cases CMS names in Arkansas; 5 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Peripheral arterial intervention | 23 | 2,979−1.4%/yr | −1.4%/yr | 7.61.2× | 45% | 2,520 in 2030−2.8%/yr |
| Dialysis access |
Superficial venous ablation in every state, and its device makers · Every procedure market in Arkansas · Every state · Compare with Florida
| ≈ 580 |
| – |
| 2026 est. | ≈ 580 | – |
| 2022 | 13 | 782 | 40% |
| 2023 | 13 | 727 | 46% |
| 2024 | 11 | 666 | 49% |
| 2025 from claims | – | 579 468–680 | 50% |
| 2026 forecast | – | 580 455–729 | 51% |
| 2027 forecast | – | 582 431–769 | 51% |
| 2028 forecast | – | 583 413–804 | 52% |
| 2029 forecast | – | 584 397–837 | 53% |
| 2030 forecast | – | 585 383–868 | 53% |
In 2025, 22% hospital outpatient, 78% office.
| +0.2%/yr |
| 9.9 |
| 98% |
| 30,300 in 2030+5.1%/yr |
| Tennessee | 54 | 5,388+1.6%/yr | +1.6%/yr | 7.3 | 100% | 5,500 in 2030+0.4%/yr |
| Georgia | 64 | 4,583−7.7%/yr | −7.7%/yr | 5.0 | 100% | 5,820 in 2030+4.1%/yr |
| North Carolina | 57 | 4,216−3.9%/yr | −3.9%/yr | 4.0 | 97% | 3,890 in 2030−1.3%/yr |
| Maryland | 43 | 3,848−12%/yr | −12%/yr | 4.3 | 100% | 3,720 in 2030−0.6%/yr |
| Virginia | 57 | 3,844−3.8%/yr | −3.8%/yr | 3.5 | 94% | 4,330 in 2030+2%/yr |
| Alabama | 29 | 2,003−5.2%/yr | −5.2%/yr | 4.3 | 85% | 2,070 in 2030+0.6%/yr |
| Louisiana | 25 | 1,654−4.9%/yr | −4.9%/yr | 3.8 | 99% | 1,580 in 2030−0.8%/yr |
| South Carolina | 27 | 1,612−7.3%/yr | −7.3%/yr | 2.3 | 96% | 1,950 in 2030+3.2%/yr |
| Mississippi | 14 | 1,432−1.3%/yr | −1.3%/yr | 3.7 | 88% | 1,870 in 2030+4.6%/yr |
| Oklahoma | 15 | 1,005−11%/yr | −11%/yr | 2.0 | 28% | 1,140 in 2030+2.2%/yr |
| Kentucky | 10 | 988−4.4%/yr | −4.4%/yr | 2.0 | 83% | 1,300 in 2030+4.7%/yr |
| West Virginia | 6 | 374−9.4%/yr | −9.4%/yr | 1.7 | 83% | 400 in 2030+1%/yr |
| Delaware | 7 | 284−5.2%/yr | −5.2%/yr | 1.6 | 100% | 440 in 2030+7.4%/yr |
| District of Columbia | 4 | 217−11%/yr | −11%/yr | 3.3 | 100% | 270 in 2030+3.5%/yr |
| 13 |
| 1,246−12%/yr |
| −12%/yr |
| 3.40.6× |
| 62% |
| 1,150 in 2030−1.3%/yr |
| Thrombectomy, IVC filters & venous stents | 6 | 614+8.4%/yr | +8.4%/yr | 1.60.9× | 5% | 680 in 2030+1.8%/yr |
| Carotid revascularization | 13 | 532−8.8%/yr | −8.8%/yr | 1.41.1× | 0% | 550 in 2030+0.4%/yr |
| Aortic endografts (EVAR/TEVAR) | 6 | 201−3.4%/yr | −3.4%/yr | 0.51.1× | 0% | 170 in 2030−3.1%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Boston Scientific leads with 71% of company spending on these surgeons in 2025, +44 pts on 2024.
In 2025, 3 companies reported engagement with Arkansas’s surgeons worth $214 in consulting, speaking, meals and travel tied to these products, about $19 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 3 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.